Fig. 3: Overexpression of C/EBPα-p42 reduces the sensitivity of FLT3 ITD AML cells to FLT3i in vivo. | Nature Communications

Fig. 3: Overexpression of C/EBPα-p42 reduces the sensitivity of FLT3 ITD AML cells to FLT3i in vivo.

From: Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia

Fig. 3: Overexpression of C/EBPα-p42 reduces the sensitivity of FLT3 ITD AML cells to FLT3i in vivo.

A Apoptosis of MV-4-11 and MOLM-13 cells with or without C/EBPα-p42 overexpression treated with DMSO, quizartinib (1, 3 nM) or gilteritinib (3, 10 nM) in MV-4-11 cells and quizartinib (3, 10 nM) or gilteritinib (10, 30 nM) in MOLM-13 cells for 48 h. B Quantification of the apoptosis changes in (A). n = 3 independent experiments. Data are Means ± SEM. Significance was analyzed by equal variance two-tailed t test. *P < 0.05, **P < 0.01, *** P < 0.001. C CellTrace™ Far Red staining of MV-4-11 and MOLM-13 cells with or without C/EBPα-p42 overexpression treated with DMSO, quizartinib or gilteritinib for 4 days. D Survival curve of B-NDG mice xenografted with MOLM-13 cells with or without C/EBPα-p42 overexpression and treated with gilteritinib (30 mg/kg, n = 10 mice), quizartinib (9 mg/kg, n = 10 mice) or 22% β-CD as the vehicle (n = 20 mice). Significance was analyzed by logrank test. *P < 0.05, **P < 0.01, *** P < 0.001. Exact p values in Source Data file. Data for all graphs in Source Data file.

Back to article page